Springworks Therapeutics Stock Return On Asset
| SWTX Stock | USD 32.64 0.81 2.54% |
SpringWorks Therapeutics fundamentals help investors to digest information that contributes to SpringWorks Therapeutics' financial success or failures. It also enables traders to predict the movement of SpringWorks Stock. The fundamental analysis module provides a way to measure SpringWorks Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SpringWorks Therapeutics stock.
Return On Assets is likely to drop to -0.47 in 2024. SpringWorks | Return On Asset |
SpringWorks Therapeutics Company Return On Asset Analysis
SpringWorks Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current SpringWorks Therapeutics Return On Asset | -0.35 |
Most of SpringWorks Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SpringWorks Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
SpringWorks Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for SpringWorks Therapeutics is extremely important. It helps to project a fair market value of SpringWorks Stock properly, considering its historical fundamentals such as Return On Asset. Since SpringWorks Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of SpringWorks Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of SpringWorks Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
SpringWorks Total Assets
Total Assets |
|
Based on the latest financial disclosure, SpringWorks Therapeutics has a Return On Asset of -0.354. This is 95.95% lower than that of the Biotechnology sector and 98.5% lower than that of the Health Care industry. The return on asset for all United States stocks is 152.86% higher than that of the company.
SpringWorks Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SpringWorks Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SpringWorks Therapeutics could also be used in its relative valuation, which is a method of valuing SpringWorks Therapeutics by comparing valuation metrics of similar companies.SpringWorks Therapeutics is currently under evaluation in return on asset category among its peers.
SpringWorks Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of SpringWorks Therapeutics from analyzing SpringWorks Therapeutics' financial statements. These drivers represent accounts that assess SpringWorks Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of SpringWorks Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.7B | 3.1B | 3.0B | 1.4B | 1.2B | 1.4B | |
| Enterprise Value | 1.3B | 3.0B | 2.9B | 1.3B | 1.2B | 1.3B |
SpringWorks Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, SpringWorks Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to SpringWorks Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
SpringWorks Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.35 | ||||
| Operating Margin | (0.75) % | ||||
| Current Valuation | 2.05 B | ||||
| Shares Outstanding | 74.27 M | ||||
| Shares Owned By Insiders | 2.01 % | ||||
| Shares Owned By Institutions | 97.99 % | ||||
| Number Of Shares Shorted | 13.7 M | ||||
| Price To Earning | 6.14 X | ||||
| Price To Book | 4.35 X | ||||
| Price To Sales | 28.13 X | ||||
| Revenue | 5.45 M | ||||
| Gross Profit | 35 M | ||||
| EBITDA | (341.35 M) | ||||
| Net Income | (325.1 M) | ||||
| Cash And Equivalents | 334.54 M | ||||
| Cash Per Share | 6.81 X | ||||
| Total Debt | 7.06 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 9.80 X | ||||
| Book Value Per Share | 7.50 X | ||||
| Cash Flow From Operations | (222.79 M) | ||||
| Short Ratio | 18.72 X | ||||
| Earnings Per Share | (4.44) X | ||||
| Target Price | 67.53 | ||||
| Number Of Employees | 305 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 2.42 B | ||||
| Total Asset | 725.79 M | ||||
| Retained Earnings | (895.03 M) | ||||
| Working Capital | 422.74 M | ||||
| Current Asset | 29.13 M | ||||
| Current Liabilities | 10.16 M | ||||
| Net Asset | 725.79 M |
About SpringWorks Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SpringWorks Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SpringWorks Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SpringWorks Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SpringWorks Stock Analysis
When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.